• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Aura Biosciences Inc.

    3/30/26 7:27:38 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AURA alert in real time by email
    S-8 1 aura-20260327.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 30, 2026

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

    AURA BIOSCIENCES, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

    32-0271970

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    80 Guest Street

    Boston, MA 02135

    (617) 500-8864

    (Address, including zip code and telephone number, including area code, of Registrant’s principal executive offices)

    Aura Biosciences, Inc. 2021 Stock Option and Incentive Plan

    Aura Biosciences, Inc. 2021 Employee Stock Purchase Plan

    (Full title of the plans)

    Elisabet de los Pinos, Ph.D.

    Chief Executive Officer

    Aura Biosciences, Inc.

    80 Guest Street

    Boston, MA 02135

    (617) 500-8864

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

     

     

     


     

    Stuart Cable, Esq.

    Danielle Lauzon, Esq.

    Stephanie A. Richards, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    (617) 570-1000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 relating to the 2021 Stock Option and Incentive Plan (the “2021 Plan”) and the 2021 Employee Stock Purchase Plan (“the “2021 ESPP”) (together, the “Plans”) of Aura Biosciences, Inc. (the “Registrant”) is being filed for the purpose of registering additional securities of the same class as other securities for which a registration statement on Form S-8 relating to the Plans has previously been filed and is effective. Accordingly, pursuant to General Instruction E, the information contained in the Registrant’s registration statements on Form S-8 (File No. 333-260589, File No. 333-263801, File No. 333-270571, File No. 333-278252, and File No. 333-286061) is hereby incorporated by reference and made a part of this Registration Statement on Form S-8, except as presented below in Part II, Item 8. Exhibits.

     

     

     


     

    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

    EXHIBIT INDEX

    Exhibit
    No.

    Description

     

     

     

     

    4.1

    Specimen Common Stock Certificate of the Registrant (Incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-260156), filed with the Securities and Exchange Commission on October 25, 2021).

     

     

     

     

    4.2

    Tenth Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect, as amended by the Certificate of Amendment, dated June 20, 2024 (Incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40971) filed with the Securities and Exchange Commission on August 8, 2024).

     

     

     

     

    4.3

    Amended and Restated Bylaws of the Registrant, as currently in effect (Incorporated by reference to Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K (File No. 001-40971) filed with the Securities and Exchange Commission on March 23, 2022).

     

     

     

     

    4.4

    Fifth Amended and Restated Investors’ Rights Agreement (Incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-260156) filed with the Securities and Exchange Commission on October 8, 2021).

     

     

     

     

    4.5

    Form of Pre-Funded Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40971) filed with the Securities and Exchange Commission on May 16, 2025).

     

     

     

     

     

    4.6

    Form of Common Stock Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K (File No. 001-40971) filed with the Securities and Exchange Commission on May 16, 2025).

     

     

     

     

     

    5.1*

    Opinion of Goodwin Procter LLP.

     

     

     

     

    23.1*

    Consent of Ernst & Young, Independent Registered Public Accounting Firm.

     

     

     

     

    23.2*

    Consent of Goodwin Procter LLP (included in Exhibit 5.1).

     

     

     

     

    24.1*

    Power of Attorney (included on signature page).

     

     

     

     

    99.1

    2021 Stock Option and Incentive Plan, and form of award agreements thereunder (Incorporated by reference to Exhibit 10.1 to the Registrant’s Registration Statement on Form S-8, as amended (File No. 333-260589), filed with the Securities and Exchange Commission on October 29, 2021).

     

     

     

     

    99.2

    2021 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-260156), filed with the Securities and Exchange Commission on October 25, 2021).

     

     

     

     

    107*

    Filing Fee Table

     

    *

    Filed herewith.

     

     

     

     


     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on this 30th day of March, 2026.

     

     

     

    AURA BIOSCIENCES, INC.

     

     

    By:

    /s/ Elisabet de los Pinos

     

    Name: Elisabet de los Pinos, Ph.D.

    Title: President and Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Elisabet de los Pinos, Ph.D., Anthony Gibney and Amy Elazzouzi, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

     

     

     

     

     

     

    Name

    Title

    Date

     

     

     

    /s/ Elisabet de los Pinos

    President, Chief Executive Officer and Director

    Principal Executive Officer

    March 30, 2026

    Elisabet de los Pinos, Ph.D.

     

     

     

    /s/ Anthony Gibney

    Anthony Gibney

     

    Chief Financial and Business Officer

    Principal Financial Officer

     

    March 30, 2026

     

     

     

     

     

    /s/ Amy Elazzouzi

    Amy Elazzouzi

    Senior Vice President, Finance

    Principal Accounting Officer

    March 30, 2026

     

     

     

    /s/ Teresa Bitetti

    Teresa Bitetti

     

    Director

     

    March 30, 2026

     

     

     

     

     

    /s/ David Johnson

    Director

    March 30, 2026

    David Johnson

     

     

     

    /s/ Giovanni Mariggi

    Director

    March 30, 2026

    Giovanni Mariggi, Ph.D.

     

     

     

    /s/ Antony Mattessich

    Director

    March 30, 2026

    Antony Mattessich

     

     

     

     

     

     

     

     


     

    /s/ Sapna Srivastava

     

    Director

     

    March 30, 2026

    Sapna Srivastava, Ph.D.

     

     

     

     

     

     

     

    /s/ Karan Takhar

     

    Director

     

    March 30, 2026

    Karan Takhar

     

     

     

     

     


    Get the next $AURA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AURA

    DatePrice TargetRatingAnalyst
    11/26/2025$13.00Outperform
    Evercore ISI
    5/28/2025$22.00Buy
    H.C. Wainwright
    7/25/2024$21.00Buy
    H.C. Wainwright
    7/27/2023Sector Outperform
    Scotiabank
    4/17/2023$38.00Buy
    BTIG Research
    7/19/2022$26.00Mkt Outperform
    JMP Securities
    11/24/2021$40.00Outperform
    SVB Leerink
    11/23/2021$38.00Buy
    BTIG Research
    More analyst ratings

    $AURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer De Los Pinos Elisabet was granted 166,000 shares, increasing direct ownership by 41% to 575,815 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    3/3/26 4:06:13 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Gibney Anthony S was granted 71,245 shares, increasing direct ownership by 34% to 278,178 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    3/3/26 4:06:39 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Kilroy Conor was granted 62,339 shares, increasing direct ownership by 37% to 229,573 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    3/3/26 4:06:58 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability Completed with New Formulation with Potential Across Non-ocular Solid Tumor Indications, Beginning with Urologic Oncology BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights. "2025 has been a year

    3/30/26 7:00:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aura Biosciences to Participate in Upcoming Investor Conferences

    BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026. Fireside Chat at 9:10 a.m. ET. Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Fireside Chat at 3:40 p.m. ET. The Citizens Life Sciences Conference on Wednesday, March 11, 2026. Fireside Chat at 11:20 a.m. ET. The live webcasts of the fireside chats will be available

    2/25/26 7:00:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference

    BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:50 a.m. ET. The live webcast of the fireside chat will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company's website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following t

    11/24/25 4:05:00 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Johnson David Michael bought $98,000 worth of shares (20,000 units at $4.90), increasing direct ownership by 14% to 166,167 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    5/20/25 5:43:51 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Gibney Anthony S bought $245,000 worth of shares (50,000 units at $4.90) and sold $7,823 worth of shares (1,519 units at $5.15), increasing direct ownership by 574% to 56,933 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    5/20/25 5:34:24 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Johnson David Michael bought $1,434,987 worth of shares (199,601 units at $7.19), increasing direct ownership by 171% to 135,667 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    11/9/23 5:02:28 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on Aura Biosciences with a new price target

    Evercore ISI resumed coverage of Aura Biosciences with a rating of Outperform and set a new price target of $13.00

    11/26/25 8:36:10 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Aura Biosciences with a new price target

    H.C. Wainwright resumed coverage of Aura Biosciences with a rating of Buy and set a new price target of $22.00

    5/28/25 9:07:05 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Aura Biosciences with a new price target

    H.C. Wainwright initiated coverage of Aura Biosciences with a rating of Buy and set a new price target of $21.00

    7/25/24 6:16:56 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    SEC Filings

    View All

    SEC Form S-8 filed by Aura Biosciences Inc.

    S-8 - Aura Biosciences, Inc. (0001501796) (Filer)

    3/30/26 7:27:38 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Aura Biosciences Inc.

    10-K - Aura Biosciences, Inc. (0001501796) (Filer)

    3/30/26 7:15:29 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aura Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Aura Biosciences, Inc. (0001501796) (Filer)

    3/30/26 7:05:19 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Leadership Updates

    Live Leadership Updates

    View All

    NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

    Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa

    11/20/25 8:00:00 PM ET
    $AURA
    $FDMT
    $NBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

    BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company's Board of Directors, effective March 31, 2025. "I am pleased to welcome Teresa to our Board of Directors," said Elisabet de los Pinos, Chief Executive Officer of Aura Biosciences. "She is a seasoned leader whose extensive operational and commercial experience will be instrumental as we advance our clinical pipeline across ocular and urologic oncology." "I am excit

    4/2/25 7:00:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

    Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "Throughout the first quarter of 2024, the Company made significant progress

    5/9/24 7:00:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/14/24 5:50:51 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/14/24 4:18:22 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/12/24 9:32:49 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care